You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

Relvar▼ Ellipta and Incruse▼ Ellipta

(fluticasone furoate/vilanterol)

Incruse & Relvar, when used together, are the only once-daily Triple Therapy combination in COPD delivered using two, intuitive Ellipta inhalers.[1],[2]

Request a placebo

Once daily combination of Incruse (55mcg) & Relvar (92/22mcg) offers your patients with COPD requiring triple therapy:

...open airways

  • Clinically meaningful, significant* and sustained 24h FEV1 improvements vs. Relvar alone.[3]

...proven exacerbation risk reduction of Relvar alone vs. LABA alone

  • In a pooled post hoc analysis of patients with an exacerbation history, Relvar reduced the risk of exacerbations by 30% (0.81/year vs. 1.11/year for vilanterol† p<0.0001)**[4]

...a simple, once-daily treatment regimen

  • Incruse & Relvar is the only once-daily Triple Therapy delivered using two, intuitive Ellipta Inhalers, with the same dosing regimen[3][4]

*Significant improvements in both studies in the primary endpoint of trough FEV1 (122mL; 124mL) vs. Relvar + Placebo at 12 weeks (92mL vs. -30mL, p<0.001; 103mL vs. -20mL, p<0.001. [3]

†Vilanterol is not licensed as monotherapy.

**Pooled analysis of two 52-week studies in 1,622 and 1,633 patients with at least one COPD exacerbation that required antibiotics and/or systemic/oral corticosteroids or hospitalisation in the 12 months prior to visit, and a smoking history of ≥10 pack-years. Primary endpoint was annual rate of moderate/severe exacerbations. [3]

References:

  1. Incruse Ellipta 55mcg SPC; GlaxoSmithKline 2015
  2. Relvar Ellipta 92/22mcg SPC; GlaxoSmithKline 2015
  3. Siler TM et al. Respir Med 2015;109:1155-1163
  4. Dransfield MT et al. Lancet Resp Med 2013;1:210-223

Relvar Ellipta was developed in collaboration with Theravance Inc 

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Incruse, Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies